2022 is an exceptional year, the world and we at Reszon Diagnostics International Sdn. Bhd. (Reszon) faced and live through the unprecedented challenges. Some, we successfully tackled them, some, we gained learning from it.
As we have witnessed COVID-19 infection peaked early this year, Malaysia experienced three COVID-19 waves – the BA.2 Omicron sub variant in April, the wave driven by the BA.4 and BA.5 sub variants in July, and the recent wave driven by the XBB variant. We are making positive impact to the community by supplying more than 20 million SALIXIUM COVID-19 Rapid Antigen Test Kits to our country and others throughout the year. The new manufacturing facilities located in USJ Subang Jaya and Puchong were established in March and April respectively to cater the growing market demand of COVID-19 rapid self-testing kits.
Growth is a journey, and in 2Q 2022, Reszon inked a manufacturing agreement with Chembio Diagnostics,Inc (Chembio), a leading point-of-care diagnostics company focused on infectious disease to manufacture Chembio HIV 1/2 STAT-PAK® Assay products in our homeland. In 3Q 2022, Reszon successfully produced the first batch of WHO-qualified HIV 1/2 STAT-PAK® Assay in the Chembio Diagnostics Malaysia (CDM) facility which we know will enable more testing thus help prevention of HIV infection worldwide.
In 4Q 2022, Reszon rose to new height as Hextar Healthcare Berhad (HHB) (formerly known as Rubberex Corp (M) Bhd) completed the acquisition of a 100% equity interest in Reszon as part of the group’s strategic business diversification into healthcare sector. This synergy will pave the way for new growth trajectories for Reszon in terms of market, networks and distribution channels, both locally and globally.
The outlook is promising for Reszon as we have gained more strength through our journey of growth which would prepare us to break through the mist and we are committed to delivering sustainable growth and returns to our shareholders.
We are grateful for all the trust and support of our employees, business partners, customers and shareholders throughout the year. It is a shared success that we could celebrate as a team. We are ready to welcome 2023 and we hope you will be part of our expedition. Together, let’s make positive impact in healthcare through Reszon’s rapid diagnostic solution!
Yours sincerely,
Katherine Koay
Sales Director of Reszon
